开立医疗：2025年上半年净利润4703.03万元

Financial Performance - For the first half of 2025, the company's operating revenue was approximately 964.26 million yuan, a decrease from 1,012.69 million yuan in the same period last year, representing a decline of about 4.78% [1] - The net profit attributable to shareholders was approximately 47.03 million yuan, down from 170.57 million yuan year-on-year, indicating a significant drop of about 72.49% [1] - The net profit after deducting non-recurring gains and losses was approximately 39.88 million yuan, compared to 154.94 million yuan in the previous year, a decrease of about 74.30% [1] - The basic earnings per share were 0.1087 yuan, down from 0.3956 yuan year-on-year [1] - The weighted average return on equity was 1.50%, a decline of 3.80 percentage points compared to the previous year [19] Cash Flow and Assets - The net cash flow from operating activities was -250.30 million yuan, a decrease of 265 million yuan compared to the previous year [22] - Total assets at the end of the reporting period were approximately 4,017.77 million yuan, down from 4,312.99 million yuan at the end of the previous year [1] - The company experienced a 99.66% decrease in trading financial assets compared to the end of the previous year, while inventory increased by 20.61% [34] Shareholder Structure - As of the end of the first half of 2025, the top ten shareholders included a new shareholder, Guangfa High-end Manufacturing Equity Fund, replacing the previous quarter's shareholder [51] - The Social Security Fund 17022 portfolio and several healthcare-focused funds increased their holdings [51] Valuation Metrics - As of August 21, the company's price-to-earnings ratio (TTM) was approximately 818.18 times, the price-to-book ratio (LF) was about 4.95 times, and the price-to-sales ratio (TTM) was around 7.85 times [1]